Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery wins Best Contract Research Organisation Award at OBN Awards 2017

Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has been named as the winner of the Best Contract Research Organisation award at the OBN Awards 2017.

The OBN Awards 2017, now in their 9th year, celebrate innovation and outstanding achievement across the UK Life Sciences industry.  Categories are broad-ranging and include Biotech, Medtech, Synthetic Biology, Digital Healthcare and Investment.  This year OBN launched a brand-new category, Best Contract Research Organisation award, which looks to recognise the critical support services provided by CROs across the pharmaceutical, biotech and medtech industries.

The awards ceremony took place on 5th October 2017 in Oxford Town Hall, an elegant and prestigious setting in central Oxford.  The evening began with a networking drinks reception, followed by dinner and the awards presentation.  There was plenty of time afterwards for celebrating and catching-up with friends and colleagues from across the pharmaceutical industry.

The Best Contract Research Organisation award was received by Sygnature Discovery’s Dr Paul Clewlow, Senior VP, Business Development, and Dr Steve Young, VP, Business Development.  The Award was sponsored by Ipsen Bioinnovation.

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.